Lisa J. Schmunk

Lisa J. Schmunk

Auto-generated profile, based on publicly available information

Lisa J. Schmunk

Hurdle.bio / Chronomics Ltd., London, UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Aging Cell
Verified
Journal Article
Open access
LSLisa J. Schmunk
Lisa J. Schmunk
TCToby P. Call
Toby P. Call
DMDaniel L. McCartney
Daniel L. McCartney
HJHira Javaid
Hira Javaid
WHWaylon J. Hastings
Waylon J. Hastings
DMDaniel E. Martin‐Herranz
Daniel E. Martin‐Herranz
Accessible and non‐invasive biomarkers that measure human ageing processes and the risk of developing age‐related disease are paramount in preventative healthcare. Here, we describe a novel framework to train saliva‐based DNA methylation (DNAm) biomarkers that are reproducible and biologically interpretable. By leveraging a reliability dataset with replicates across tissues, we demonstrate that it is possible to transfer knowledge from blood DNAm to saliva DNAm data using DNAm proxies of blood proteins (EpiScores). We apply these methods to create a new saliva‐based epigenetic clock (InflammAge) that quantifies systemic chronic inflammation (SCI) in humans. Using a large blood DNAm human cohort with linked electronic health records and over 18,000 individuals (Generation Scotland), we demonstrate that InflammAge significantly associates with all‐cause mortality, disease outcomes, lifestyle factors, and immunosenescence; in many cases outperforming the widely used SCI biomarker C‐reactive protein (CRP). We propose that our biomarker discovery framework and InflammAge will be useful to improve understanding of the molecular mechanisms underpinning human ageing and to assess the impact of gero‐protective interventions.

9 September 2025 in Emerging Topics in Life Sciences
Verified
Journal Article
Open access
HJHira Javaid
Hira Javaid
CPConstantin Cezar Petrescu
Constantin Cezar Petrescu
LSLisa J. Schmunk
Lisa J. Schmunk
JMJack M. Monahan
Jack M. Monahan
POPaul O'Reilly
Paul O'Reilly
DMDaniel E. Martin-Herranz
Daniel E. Martin-Herranz
Artificial intelligence (AI) is transforming many fields, including healthcare and medicine. In biomarker discovery, AI algorithms have had a profound impact, thanks to their ability to derive insights from complex high-dimensional datasets and integrate multi-modal datatypes (such as omics, electronic health records, imaging or sensor and wearable data). However, despite the proliferation of AI-powered biomarkers, significant hurdles still remain in translating them to the clinic and driving adoption, including lack of population diversity, difficulties accessing harmonised data, costly and time-consuming clinical studies, evolving AI regulatory frameworks and absence of scalable diagnostic infrastructure. Here, we provide an overview of the AI toolkit available for biomarker discovery, and we discuss exciting examples of AI-powered biomarkers across therapeutic areas. Finally, we address the challenges ahead of us to ensure that these technologies reach patients and users globally and unlock a new era of fast innovation for precision medicine.

23 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLisa J. Schmunk
Lisa J. Schmunk
TCToby P. Call
Toby P. Call
DMDaniel L. McCartney
Daniel L. McCartney
HJHira Javaid
Hira Javaid
WHWaylon J. Hastings
Waylon J. Hastings
DMDaniel E. Martin-Herranz
Daniel E. Martin-Herranz
Accessible and non-invasive biomarkers that measure human ageing processes and the risk of developing age-related disease are paramount in preventative healthcare. In this study, we describe a novel framework to train saliva-based DNA methylation (DNAm) biomarkers that are reproducible and biologically interpretable. By leveraging a reliability dataset with replicates across tissues, we demonstrate that it is possible to transfer knowledge from blood DNAm data to saliva DNAm data using DNAm proxies of blood proteins (EpiScores). We then apply these methods to create a new saliva-based epigenetic clock (InflammAge) that quantifies systemic chronic inflammation (SCI) in humans. Using a large blood DNAm human cohort with linked electronic health records and over 18,000 individuals (Generation Scotland), we demonstrate that InflammAge significantly associates with all-cause mortality, disease outcomes, lifestyle factors and immunosenescence; in many cases outperforming the widely used SCI biomarker C-reactive protein (CRP). We propose that our biomarker discovery framework and InflammAge will be useful to improve our understanding of the molecular mechanisms underpinning human ageing and to assess the impact of gero-protective interventions.